GlaxoSmithKline CR`s Net Debt/Equity reached -13.8 % in 2017. This is 40.1 % less than in the previous year.
Buy Net Debt/Equity data for GlaxoSmithKline Czech Republic.
$19.99Buy all data for GlaxoSmithKline Czech Republic.
Buy annual subscriptions for all our products.
| Company | Unit | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
| Amgen Czech Republic | % | ... | ... | ... | ... | ... | 0 | 0 | -0.133 | 18.6 | 38.7 | ||||||||
| Bayer Czech Republic | % | ... | ... | ... | -10.9 | -3.80 | 6.64 | 8.88 | 60.8 | ||||||||||
| GlaxoSmithKline Czech Republic | % | ... | ... | ... | 9.97 | 17.5 | 23.8 | -0.015 | -38.5 | ||||||||||
| Merck Czech Republic | % | ... | ... | 55.8 | 40.2 | 43.6 | 5.40 | -0.588 | |||||||||||
| Novartis Czech Republic | % | 83.3 | 16.7 | -1.34 | 22.0 | -0.390 | |||||||||||||
| Pfizer Czech Republic | % | ... | ... | 66.1 | -8.43 | -1.56 | -16.8 | -0.350 | |||||||||||
| Roche Czech Republic | % | ... | ... | ... | -0.035 | 13.7 | 23.0 | 47.7 | 55.7 | ... | |||||||||
| Sanofi-Aventis Czech Republic | % | ... | ... | ... | ... | 221 | 232 | 137 | 73.7 | 57.8 | |||||||||
| Servier Czech Republic | % | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | -89.2 | -89.7 | -59.8 | -26.5 | ||
| Walmark | % | ... | ... | ... | 13.3 | 195 | 86.8 | 73.0 | -1,526 |
Helgi Library 
